{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:23:04Z","timestamp":1778750584460,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00011-025-02011-w","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T12:41:14Z","timestamp":1741092074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring druggable targets and inflammation-mediated pathways in cancer: a Mendelian randomization analysis integrating transcriptomic and proteomic data"],"prefix":"10.1007","volume":"74","author":[{"given":"Hao","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changqing","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"2011_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"2011_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2011_CR3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1186\/s12967-023-04525-5","volume":"21","author":"F Ren","year":"2023","unstructured":"Ren F, Jin Q, Liu T, Ren X, Zhan Y. Proteome-wide mendelian randomization study implicates therapeutic targets in common cancers. J Transl Med. 2023;21:646.","journal-title":"J Transl Med"},{"key":"2011_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1476-4598-12-48","volume":"12","author":"J Surmacki","year":"2013","unstructured":"Surmacki J, Musial J, Kordek R, Abramczyk H. Raman imaging at biological interfaces: applications in breast cancer diagnosis. Mol Cancer. 2013;12:48.","journal-title":"Mol Cancer"},{"key":"2011_CR5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","volume":"54","author":"HY Min","year":"2022","unstructured":"Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54:1670\u201394.","journal-title":"Exp Mol Med"},{"key":"2011_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s10194-024-01828-w","volume":"25","author":"X Sun","year":"2024","unstructured":"Sun X, Chen B, Qi Y, Wei M, Chen W, Wu X, et al. Multi-omics Mendelian randomization integrating GWAS, eQTL and pQTL data revealed GSTM4 as a potential drug target for migraine. J Headache Pain. 2024;25:117.","journal-title":"J Headache Pain"},{"key":"2011_CR7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrd.2016.85","volume":"15","author":"K Smietana","year":"2016","unstructured":"Smietana K, Siatkowski M, M\u00f8ller M. Trends in clinical success rates. Nat Rev Drug Discov. 2016;15:379\u201380.","journal-title":"Nat Rev Drug Discov"},{"key":"2011_CR8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nrd.2016.184","volume":"15","author":"RK Harrison","year":"2016","unstructured":"Harrison RK. Phase II and phase III failures: 2013\u20132015. Nat Rev Drug Discov. 2016;15:817\u20138.","journal-title":"Nat Rev Drug Discov"},{"key":"2011_CR9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nrc.2017.82","volume":"17","author":"A Sud","year":"2017","unstructured":"Sud A, Kinnersley B, Houlston RS. Genome-wide association studies of cancer: current insights and future perspectives. Nat Rev Cancer. 2017;17:692\u2013704.","journal-title":"Nat Rev Cancer"},{"key":"2011_CR10","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/jnnp-2023-331142","volume":"94","author":"WM Su","year":"2023","unstructured":"Su WM, Gu XJ, Dou M, Duan QQ, Jiang Z, Yin KF, et al. Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2023;94:954\u201361.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2011_CR11","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","volume":"23","author":"G Davey Smith","year":"2014","unstructured":"Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23:R89-98.","journal-title":"Hum Mol Genet"},{"key":"2011_CR12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/014107680710000923","volume":"100","author":"SG Davey","year":"2007","unstructured":"Davey SG. Capitalizing on Mendelian randomization to assess the effects of treatments. J R Soc Med. 2007;100:432\u20135.","journal-title":"J R Soc Med"},{"key":"2011_CR13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tig.2022.08.005","volume":"39","author":"P Kreitmaier","year":"2023","unstructured":"Kreitmaier P, Katsoula G, Zeggini E. Insights from multi-omics integration in complex disease primary tissues. Trends Genet TIG. 2023;39:46\u201358.","journal-title":"Trends Genet TIG"},{"key":"2011_CR14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1126\/scitranslmed.aag1166","volume":"9","author":"C Finan","year":"2017","unstructured":"Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9:383.","journal-title":"Sci Transl Med"},{"key":"2011_CR15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ng.3538","volume":"48","author":"Z Zhu","year":"2016","unstructured":"Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48:481\u20137.","journal-title":"Nat Genet"},{"key":"2011_CR16","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493-503.","journal-title":"Lancet Oncol"},{"key":"2011_CR17","first-page":"n2233","volume":"375","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ Clin Res Ed. 2021;375:n2233.","journal-title":"BMJ Clin Res Ed"},{"key":"2011_CR18","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","volume":"53","author":"U V\u00f5sa","year":"2021","unstructured":"V\u00f5sa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53:1300\u201310.","journal-title":"Nat Genet"},{"key":"2011_CR19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622:329\u201338.","journal-title":"Nature"},{"key":"2011_CR20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41590-023-01588-w","volume":"24","author":"JH Zhao","year":"2023","unstructured":"Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman \u00c5K, Kalnapenkis A, et al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol. 2023;24:1540\u201351.","journal-title":"Nat Immunol"},{"key":"2011_CR21","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1038\/s41467-021-26280-1","volume":"12","author":"CS Storm","year":"2021","unstructured":"Storm CS, Kia DA, Almramhi MM, Bandres-Ciga S, Finan C, Hingorani AD, et al. Finding genetically-supported drug targets for Parkinson\u2019s disease using Mendelian randomization of the druggable genome. Nat Commun. 2021;12:7342.","journal-title":"Nat Commun"},{"key":"2011_CR22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512\u201325.","journal-title":"Int J Epidemiol"},{"key":"2011_CR23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693\u20138.","journal-title":"Nat Genet"},{"key":"2011_CR24","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/ije\/dyy101","volume":"47","author":"J Bowden","year":"2018","unstructured":"Bowden J, Spiller W, Del Greco MF, Sheehan N, Thompson J, Minelli C, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the radial plot and radial regression. Int J Epidemiol. 2018;47:1264\u201378.","journal-title":"Int J Epidemiol"},{"key":"2011_CR25","doi-asserted-by":"crossref","first-page":"e1004383","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383.","journal-title":"PLoS Genet"},{"key":"2011_CR26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41588-018-0184-y","volume":"50","author":"W Zhou","year":"2018","unstructured":"Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, Wolford BN, et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet. 2018;50:1335\u201341.","journal-title":"Nat Genet"},{"key":"2011_CR27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400\u201314.","journal-title":"Nat Rev Cancer"},{"key":"2011_CR28","doi-asserted-by":"crossref","first-page":"17488","DOI":"10.3390\/ijms242417488","volume":"24","author":"E Manousakis","year":"2023","unstructured":"Manousakis E, Miralles CM, Esquerda MG, Wright RHG. CDKN1A\/p21 in breast cancer: part of the problem, or part of the solution? Int J Mol Sci. 2023;24:17488.","journal-title":"Int J Mol Sci"},{"key":"2011_CR29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41419-022-04676-1","volume":"13","author":"Y Huang","year":"2022","unstructured":"Huang Y, Zhu Y, Yang J, Pan Q, Zhao J, Song M, et al. CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma. Cell Death Dis. 2022;13:251.","journal-title":"Cell Death Dis"},{"key":"2011_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11010-013-1696-5","volume":"382","author":"M Askari","year":"2013","unstructured":"Askari M, Sobti RC, Nikbakht M, Sharma SC. Aberrant promoter hypermethylation of p21 (WAF1\/CIP1) gene and its impact on expression and role of polymorphism in the risk of breast cancer. Mol Cell Biochem. 2013;382:19\u201326.","journal-title":"Mol Cell Biochem"},{"key":"2011_CR31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/35060032","volume":"3","author":"BP Zhou","year":"2001","unstructured":"Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1\/WAF1 by Akt-induced phosphorylation in HER-2\/neu-overexpressing cells. Nat Cell Biol. 2001;3:245\u201352.","journal-title":"Nat Cell Biol"},{"key":"2011_CR32","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/abbs\/gmy129","volume":"50","author":"L Wang","year":"2018","unstructured":"Wang L, Wang R, Ye Z, Wang Y, Li X, Chen W, et al. PVT1 affects EMT and cell proliferation and migration via regulating p21 in triple-negative breast cancer cells cultured with mature adipogenic medium. Acta Biochim Biophys Sin. 2018;50:1211\u20138.","journal-title":"Acta Biochim Biophys Sin"},{"key":"2011_CR33","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1158\/0008-5472.CAN-04-3468","volume":"65","author":"W Sangrar","year":"2005","unstructured":"Sangrar W, Zirgnibl RA, Gao Y, Muller WJ, Jia Z, Greer PA. An identity crisis for Fps\/Fes: oncogene or tumor suppressor? Can Res. 2005;65:3518\u201322.","journal-title":"Can Res"},{"key":"2011_CR34","first-page":"89","volume":"34","author":"S Kanda","year":"2009","unstructured":"Kanda S, Miyata Y, Kanetake H, Smithgall TE. Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells. Int J Oncol. 2009;34:89\u201396.","journal-title":"Int J Oncol"},{"key":"2011_CR35","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.1074\/jbc.M113.450593","volume":"288","author":"Q Ye","year":"2013","unstructured":"Ye Q, Kantonen S, Henkels KM, Gomez-Cambronero J. A new signaling pathway (JAK-Fes-phospholipase D) that is enhanced in highly proliferative breast cancer cells. J Biol Chem. 2013;288:9881\u201391.","journal-title":"J Biol Chem"},{"key":"2011_CR36","doi-asserted-by":"crossref","first-page":"116336","DOI":"10.1016\/j.biopha.2024.116336","volume":"173","author":"M Yang","year":"2024","unstructured":"Yang M, Li Q, Yang H, Li Y, Lu L, Wu X, et al. Downregulation of PDIA3 inhibits gastric cancer cell growth through cell cycle regulation. Biomed Pharmacother. 2024;173:116336.","journal-title":"Biomed Pharmacother"},{"key":"2011_CR37","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.4238\/2015.June.26.4","volume":"14","author":"FS Ramos","year":"2015","unstructured":"Ramos FS, Serino LT, Carvalho CM, Lima RS, Urban CA, Cavalli IJ, et al. PDIA3 and PDIA6 gene expression as an aggressiveness marker in primary ductal breast cancer. Genet Mol Res GMR. 2015;14:6960\u20137.","journal-title":"Genet Mol Res GMR"},{"key":"2011_CR38","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s12272-012-1018-6","volume":"35","author":"MN Song","year":"2012","unstructured":"Song MN, Moon PG, Lee JE, Na M, Kang W, Chae YS, et al. Proteomic analysis of breast cancer tissues to identify biomarker candidates by gel-assisted digestion and label-free quantification methods using LC-MS\/MS. Arch Pharmacal Res. 2012;35:1839\u201347.","journal-title":"Arch Pharmacal Res"},{"key":"2011_CR39","doi-asserted-by":"crossref","first-page":"39247","DOI":"10.18632\/oncotarget.5746","volume":"6","author":"M Hussmann","year":"2015","unstructured":"Hussmann M, Janke K, Kranz P, Neumann F, Mersch E, Baumann M, et al. Depletion of the thiol oxidoreductase ERp57 in tumor cells inhibits proliferation and increases sensitivity to ionizing radiation and chemotherapeutics. Oncotarget. 2015;6:39247\u201361.","journal-title":"Oncotarget"},{"key":"2011_CR40","doi-asserted-by":"crossref","first-page":"BSR20193271","DOI":"10.1042\/BSR20193271","volume":"40","author":"HS Young","year":"2020","unstructured":"Young HS, McGowan LM, Jepson KA, Adams JC. Impairment of cell adhesion and migration by inhibition of protein disulphide isomerases in three breast cancer cell lines. Biosci Rep. 2020;40:BSR20193271.","journal-title":"Biosci Rep"},{"key":"2011_CR41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","volume":"14","author":"J Hu","year":"2021","unstructured":"Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B, et al. Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol. 2021;14:157.","journal-title":"J Hematol Oncol"},{"key":"2011_CR42","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.4161\/cc.22852","volume":"11","author":"WH Chappell","year":"2012","unstructured":"Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle. 2012;11:4579\u201388.","journal-title":"Cell Cycle"},{"key":"2011_CR43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3892\/mmr.2020.11121","volume":"22","author":"J Li","year":"2020","unstructured":"Li J, Li Y, Chen L, Yu B, Xue Y, Guo R, et al. p53\/PGC-1\u03b1-mediated mitochondrial dysfunction promotes PC3 prostate cancer cell apoptosis. Mol Med Rep. 2020;22:155\u201364.","journal-title":"Mol Med Rep"},{"key":"2011_CR44","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1158\/0008-5472.CAN-23-2910","volume":"84","author":"YA Yoo","year":"2024","unstructured":"Yoo YA, Quan S, Yang W, Guo Q, Rodr\u00edguez Y, Chalmers ZR, et al. Asparagine dependency is a targetable metabolic vulnerability in TP53-altered castration-resistant prostate cancer. Can Res. 2024;84:3004\u201322.","journal-title":"Can Res"},{"key":"2011_CR45","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1091\/mbc.11.10.3289","volume":"11","author":"W Antonin","year":"2000","unstructured":"Antonin W, Holroyd C, Tikkanen R, H\u00f6ning S, Jahn R. The R-SNARE endobrevin\/VAMP-8 mediates homotypic fusion of early endosomes and late endosomes. Mol Biol Cell. 2000;11:3289\u201398.","journal-title":"Mol Biol Cell"},{"key":"2011_CR46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1083\/jcb.201411093","volume":"210","author":"MR Marshall","year":"2015","unstructured":"Marshall MR, Pattu V, Halimani M, Maier-Peuschel M, M\u00fcller ML, Becherer U, et al. VAMP8-dependent fusion of recycling endosomes with the plasma membrane facilitates T lymphocyte cytotoxicity. J Cell Biol. 2015;210:135\u201351.","journal-title":"J Cell Biol"},{"key":"2011_CR47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/neuonc\/nou219","volume":"17","author":"Y Chen","year":"2015","unstructured":"Chen Y, Meng D, Wang H, Sun R, Wang D, Wang S, et al. VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells. Neuro Oncol. 2015;17:407\u201318.","journal-title":"Neuro Oncol"},{"key":"2011_CR48","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1038\/s41467-021-26824-5","volume":"12","author":"H Huang","year":"2021","unstructured":"Huang H, Ouyang Q, Zhu M, Yu H, Mei K, Liu R. mTOR-mediated phosphorylation of VAMP8 and SCFD1 regulates autophagosome maturation. Nat Commun. 2021;12:6622.","journal-title":"Nat Commun"},{"key":"2011_CR49","volume":"12","author":"X Wang","year":"2023","unstructured":"Wang X, Xu F, Kou H, Zheng Y, Yang J, Xu Z, et al. Stromal cell-derived small extracellular vesicles enhance radioresistance of prostate cancer cells via interleukin-8-induced autophagy. J Extracell Vesicles. 2023;12: e12342.","journal-title":"J Extracell Vesicles"},{"key":"2011_CR50","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1080\/15548627.2021.1962682","volume":"17","author":"A Mukha","year":"2021","unstructured":"Mukha A, Kahya U, Dubrovska A. Targeting glutamine metabolism and autophagy: the combination for prostate cancer radiosensitization. Autophagy. 2021;17:3879\u201381.","journal-title":"Autophagy"},{"key":"2011_CR51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2407-10-32","volume":"10","author":"Y Wu","year":"2010","unstructured":"Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer. 2010;10:32.","journal-title":"BMC Cancer"},{"key":"2011_CR52","doi-asserted-by":"crossref","first-page":"R681","DOI":"10.1186\/bcr1274","volume":"7","author":"W Zoli","year":"2005","unstructured":"Zoli W, Ulivi P, Tesei A, Fabbri F, Rosetti M, Maltoni R, et al. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res BCR. 2005;7:R681\u20139.","journal-title":"Breast Cancer Res BCR"},{"key":"2011_CR53","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.3390\/ijms25073950","volume":"25","author":"M Krishnamohan","year":"2024","unstructured":"Krishnamohan M, Kaplanov I, Maudi-Boker S, Yousef M, Machluf-Katz N, Cohen I, et al. Tumor cell-associated IL-1\u03b1 affects breast cancer progression and metastasis in mice through manipulation of the tumor immune microenvironment. Int J Mol Sci. 2024;25:3950.","journal-title":"Int J Mol Sci"},{"key":"2011_CR54","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41419-018-0876-3","volume":"9","author":"N Wang","year":"2018","unstructured":"Wang N, Liu W, Zheng Y, Wang S, Yang B, Li M, et al. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-\u03baB\/SOX4 signaling. Cell Death Dis. 2018;9:880.","journal-title":"Cell Death Dis"},{"key":"2011_CR55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12964-021-00775-2","volume":"19","author":"J Li","year":"2021","unstructured":"Li J, Wang S, Wang N, Zheng Y, Yang B, Wang X, et al. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM\/CXCL1-induced Treg differentiation and infiltration. Cell Commun Signal. 2021;19:89.","journal-title":"Cell Commun Signal"},{"key":"2011_CR56","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.3390\/cells11233717","volume":"11","author":"M Kundu","year":"2022","unstructured":"Kundu M, Greer YE, Dine JL, Lipkowitz S. Targeting TRAIL death receptors in triple-negative breast cancers: challenges and strategies for cancer therapy. Cells. 2022;11:3717.","journal-title":"Cells"},{"key":"2011_CR57","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2007.15.7198","volume":"26","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2\/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L\/TRAIL). J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:3621\u201330.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2011_CR58","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1111\/cas.14995","volume":"112","author":"J Meng","year":"2021","unstructured":"Meng J, Wang L, Hou J, Yang X, Lin K, Nan H, et al. CCL23 suppresses liver cancer progression through the CCR1\/AKT\/ESR1 feedback loop. Cancer Sci. 2021;112:3099\u2013110.","journal-title":"Cancer Sci"},{"key":"2011_CR59","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bju.12452","volume":"113","author":"DP Nguyen","year":"2014","unstructured":"Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014;113:986\u201392.","journal-title":"BJU Int"},{"key":"2011_CR60","first-page":"006020","volume":"11","author":"S Chen","year":"2023","unstructured":"Chen S, Lu K, Hou Y, You Z, Shu C, Wei X, et al. YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6. J Immunother Cancer. 2023;11:006020.","journal-title":"J Immunother Cancer"},{"key":"2011_CR61","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14737140.2018.1449648","volume":"18","author":"D Shen","year":"2018","unstructured":"Shen D, Yu X, Wu Y, Chen Y, Li G, Cheng F, et al. Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers. Expert Rev Anticancer Ther. 2018;18:487\u201399.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2011_CR62","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/s41388-019-1070-5","volume":"39","author":"L Hu","year":"2020","unstructured":"Hu L, Sun Y, Luo J, He X, Ye M, Li G, et al. Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression. Oncogene. 2020;39:1891\u2013903.","journal-title":"Oncogene"},{"key":"2011_CR63","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jep.2016.06.061","volume":"190","author":"Z Gholamnezhad","year":"2016","unstructured":"Gholamnezhad Z, Havakhah S, Boskabady MH. Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: a review. J Ethnopharmacol. 2016;190:372\u201386.","journal-title":"J Ethnopharmacol"},{"key":"2011_CR64","first-page":"28","volume":"706","author":"SA el Arafa","year":"2011","unstructured":"el Arafa SA, Zhu Q, Shah ZI, Wani G, Barakat BM, Racoma I, et al. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res. 2011;706:28\u201335.","journal-title":"Mutat Res"},{"key":"2011_CR65","first-page":"3592","volume":"38","author":"B Kou","year":"2017","unstructured":"Kou B, Liu W, Zhao W, Duan P, Yang Y, Yi Q, et al. Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-\u03b2\/Smad2\/3 signaling pathway. Oncol Rep. 2017;38:3592\u20138.","journal-title":"Oncol Rep"},{"key":"2011_CR66","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/1097-0045(20000901)44:4<313::AID-PROS8>3.0.CO;2-D","volume":"44","author":"RG Schipper","year":"2000","unstructured":"Schipper RG, Deli G, Deloyer P, Lange WP, Schalken JA, Verhofstad AA. Antitumor activity of the polyamine analog N(1), N(11)-diethylnorspermine against human prostate carcinoma cells. Prostate. 2000;44:313\u201321.","journal-title":"Prostate"},{"key":"2011_CR67","first-page":"379","volume":"19","author":"CM Holst","year":"2005","unstructured":"Holst CM, Oredsson SM. Comparison of three cytotoxicity tests in the evaluation of the cytotoxicity of a spermine analogue on human breast cancer cell lines. Toxicol in vitro Int J Publ Assoc BIBRA. 2005;19:379\u201387.","journal-title":"Toxicol in vitro Int J Publ Assoc BIBRA"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02011-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-025-02011-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02011-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:54:06Z","timestamp":1767200046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-025-02011-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2011"],"URL":"https:\/\/doi.org\/10.1007\/s00011-025-02011-w","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ethical approval was not applicable because this study used data from publicly available databases.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"46"}}